# Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH

Study · id `cardio:ct-nct02725372` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02725372](<https://clinicaltrials.gov/study/NCT02725372>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02725372

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 207 participants.

## Technical summary

Registry record NCT02725372. Randomized; quadruple masking; primary purpose treatment. Start 2016-04 (actual); primary completion 2018-08 (actual). Results posted on 2023-01-25.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 207 participants (enrolled count; ClinicalTrials.gov record NCT02725372, source copy `cardio:ctgov-nct02725372-2023-02-21`, retrieved 2026-10-31)
- Started: 2016-04 (actual) (ClinicalTrials.gov record NCT02725372, source copy `cardio:ctgov-nct02725372-2023-02-21`, retrieved 2026-10-31)
- Primary completion: 2018-08 (actual) (ClinicalTrials.gov record NCT02725372, source copy `cardio:ctgov-nct02725372-2023-02-21`, retrieved 2026-10-31)
- Completion: 2018-08 (actual) (ClinicalTrials.gov record NCT02725372, source copy `cardio:ctgov-nct02725372-2023-02-21`, retrieved 2026-10-31)
- Results first posted: 2023-01-25 (ClinicalTrials.gov record NCT02725372, source copy `cardio:ctgov-nct02725372-2023-02-21`, retrieved 2026-10-31)
- Countries: United States; Australia; Austria; Belgium; Canada; Colombia; Croatia; Czechia; France; Germany; Israel; Italy; Netherlands; Portugal; Serbia; Spain; Ukraine; United Kingdom (ClinicalTrials.gov record NCT02725372, source copy `cardio:ctgov-nct02725372-2023-02-21`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02725372-2023-02-21`, retrieved 2026-10-31)

## The registry's words

- Brief title: Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH
- Acronym: INOvation-1
- Condition: Pulmonary Arterial Hypertension
- Intervention (Drug): Inhaled Nitric Oxide 75 mcg/kg IBW/hr
- Intervention (Drug): Placebo
- Lead sponsor: Bellerophon Pulse Technologies
- Lead sponsor class: INDUSTRY
- Collaborator: Worldwide Clinical Trials
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: Bellerophon Pulse Technologies (`cardio:org-bellerophon-pulse-technologies`)
- Registry lists this organization as a collaborator: Worldwide Clinical Trials (`cardio:org-worldwide-clinical-trials`)

## Provenance

Content hash: 11df83d5d9bd51347dc14ad5ddf1aabbb277e771483302bab1986da9cc1dfbae
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
